This prestigious honor recognizes her contributions and leadership in antiviral drug discovery and development.
The International Society for Antiviral Research (ISAR) honored Jinhong Chang, MD, PhD, Harvey J. Alter Professor and vice president of the Baruch S. Blumberg Institute, with the Alice Ball Excellence Award last week at ISAR’s annual conference in Prague.
The award is presented annually to a scientist who has made significant contributions to antiviral research and is widely recognized within their field for high‑impact scientific work.
In honoring the special legacy of Alice Ball, nominees must have demonstrated actual or emerging leadership in advancing equity within antiviral research. This includes meaningful efforts to promote, support or expand participation among individuals or communities who have faced collective or individual barriers in pursuing careers or contributions in this field.
Dr. Chang was recognized for her scientific excellence and leadership in antiviral drug discovery and development, including advancing innovative approaches from early-stage discovery research through preclinical and translational development.
Dr. Chang accepting the Alice Ball Award from ISAR President Luis Schang.
At the conference, Dr. Chang delivered the award recipient presentation titled “A 15‑Year Academic Journey: Discovery and Development of a Small Molecule Drug Candidate for Yellow Fever” to highlight the history and exciting progress of a fully in-house effort at Blumberg Institute to develop a first-in-class yellow fever virus NS4B inhibitor. She emphasized the importance of long-term collaboration and illustrated how translational virology can drive innovation in antiviral drug discovery and development.
Dr. Chang expressed appreciation to ISAR, crediting the organization for fostering collaborations that have helped advance her work. She also acknowledged her colleagues and lab members for their contributions and said: “I accept this award on behalf of a broader community. This honor belongs to all of us, and I look forward to what we will build together.”
About the Baruch S. Blumberg Institute: An independent, nonprofit research organization, the Blumberg Institute was launched in 2003 by the Hepatitis B Foundation. Today, the Institute is a leading center for translational research in hepatitis B, liver cancer and related diseases. Our scientists primarily focus on understanding the pathobiology of hepatitis B virus and related diseases, developing diagnostics for early detection of liver cancer and therapeutics for the cure of chronic hepatitis B. Their research extends to investigating other RNA viruses causing hepatitis and hemorrhagic fever and developing antiviral drugs and immune modulators to treat these viral diseases.
This prestigious honor recognizes her contributions and leadership in antiviral drug discovery and development.
The International Society for Antiviral Research (ISAR) honored Jinhong Chang, MD, PhD, Harvey J. Alter Professor and vice president of the Baruch S. Blumberg Institute, with the Alice Ball Excellence Award last week at ISAR’s annual conference in Prague.
The award is presented annually to a scientist who has made significant contributions to antiviral research and is widely recognized within their field for high‑impact scientific work.
In honoring the special legacy of Alice Ball, nominees must have demonstrated actual or emerging leadership in advancing equity within antiviral research. This includes meaningful efforts to promote, support or expand participation among individuals or communities who have faced collective or individual barriers in pursuing careers or contributions in this field.
Dr. Chang was recognized for her scientific excellence and leadership in antiviral drug discovery and development, including advancing innovative approaches from early-stage discovery research through preclinical and translational development.
At the conference, Dr. Chang delivered the award recipient presentation titled “A 15‑Year Academic Journey: Discovery and Development of a Small Molecule Drug Candidate for Yellow Fever” to highlight the history and exciting progress of a fully in-house effort at Blumberg Institute to develop a first-in-class yellow fever virus NS4B inhibitor. She emphasized the importance of long-term collaboration and illustrated how translational virology can drive innovation in antiviral drug discovery and development.
Dr. Chang expressed appreciation to ISAR, crediting the organization for fostering collaborations that have helped advance her work. She also acknowledged her colleagues and lab members for their contributions and said: “I accept this award on behalf of a broader community. This honor belongs to all of us, and I look forward to what we will build together.”
About the Baruch S. Blumberg Institute: An independent, nonprofit research organization, the Blumberg Institute was launched in 2003 by the Hepatitis B Foundation. Today, the Institute is a leading center for translational research in hepatitis B, liver cancer and related diseases. Our scientists primarily focus on understanding the pathobiology of hepatitis B virus and related diseases, developing diagnostics for early detection of liver cancer and therapeutics for the cure of chronic hepatitis B. Their research extends to investigating other RNA viruses causing hepatitis and hemorrhagic fever and developing antiviral drugs and immune modulators to treat these viral diseases.